MedTrace Logo

AZD9773 Dose Escalation Study

NCT00615017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-08-22

Study results available
· View outcomes & findings →

Summary

This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.

Conditions

  • Severe Sepsis

Interventions

DRUG

AZD9773 (CytoFab)

intravenous infusions

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Steven Simonson, MD · AstraZeneca

  • Wayne Dankner, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615017 on ClinicalTrials.gov